SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Intelligent Bio Solutions, Inc. is a medical technology company, which engages in delivering testing solutions. It operates through the Intelligent Fingerprinting Products (IFPG) and Saliva Glucose Biosensor Platform (SGBP) segments. It offers biochemistry, immunology, tumor markers, hormones, and nucleic acid diagnostic modalities. The company was founded on December 5, 2016 and is headquartered in New York, NY.

Intelligent Bio Solutions Inc

Intelligent Bio Solutions (INBS) is trending following news of a strategic manufacturing partnership aimed at significantly reducing production costs and expanding capacity, which has driven substantial intraday stock volatility. The community is actively discussing the stock's low float and high trading volume, fueling speculation about a potential short squeeze and anticipating further upward movement as it tests key resistance levels. This partnership is seen as a crucial step for scaling their fingerprint drug screening technology ahead of anticipated future market expansion.

Litecoin is a peer-to-peer cryptocurrency created by Charlie Lee. It was created based on the Bitcoin protocol but differs in terms of the hashing algorithm used. Litecoin uses the memory intensive Scrypt proof of work mining algorithm. Scrypt allows consumer-grade hardware such as GPU to mine those coins.  Why Litecoin? Litecoin is a cryptocurrency that has evolved from Bitcoin after its own popularity in the industry, this alternative, or ‘altcoin’ has emerged to allow investors to diversify their digital currency package, according to Investopedia. Litecoin is one of the most prominent altcoins and was created by former Google employee and Director of Engineering at Coinbase, Charlie Lee. Litecoin was the first to alter Bitcoin and the most significant difference is that it takes 2.5 minutes for Litecoin to generate a block, or transaction, in comparison to Bitcoin's 10 minutes.  ‘While this matters little to traders, miners who use hardware to run Bitcoin's network cannot switch over to Litecoin. This keeps bigger mining conglomerates away from Litecoin because they cannot easily optimize their profits by swapping to another coin, contributing to a more decentralized experience. Litecoin also has bigger blocks, and more coins in circulation, making it more affordable and swift when transacting,’ Investopedia explained.  As explained above, Litecoin can transact a lot faster than Bitcoin, but there are also a number of other characteristics that investors need to know before trading. Litecoin can handle higher volumes of transactions because of the capability of transacting faster and if Bitcoin attempted to transact on the scale of its altcoin, a code update would be needed. However, Litecoin’s blocks would be larger, but with more ‘orphaned blocks'. The faster block time of litecoin reduces the risk of double spending attacks - this is theoretical in the case of both networks having the same hashing power.  Litecoin Technical Details: The transaction confirmation time taken for Litecoin is about 2.5 minutes on average (as compared to Bitcoin's 10 minutes). The Litecoin network is scheduled to cap at 84 million currency units.   Litecoin has inspired many other popular alternative currencies (eg. Dogecoin) because of its Scrypt hashing algorithm in order to prevent ASIC miners from mining those coins. However it is said that by the end of this year, Scrypt ASIC will enter the mass market.

Litecoin

Litecoin is trending due to recent discussions surrounding its integration as a fuel-discount token within the EzFill app, generating buzz about its expanding utility. The community is sharply divided, with many anticipating significant future appreciation from multi-year lows and viewing it as "digital silver," while others express frustration over its recent price action and struggle to overcome key resistance levels.

Dogecoin is a cryptocurrency based on the popular "Doge" Internet meme and features a Shiba Inu on its logo. Dogecoin is a Litecoin fork. Introduced as a "joke currency" on 6 December 2013, Dogecoin quickly developed its own online community and reached a capitalization of US$60 million in January 2014. Compared with other cryptocurrencies, Dogecoin had a fast initial coin production schedule: 100 billion coins were in circulation by mid-2015, with an additional 5.256 billion coins every year thereafter. As of 30 June 2015, the 100 billionth Dogecoin had been mined.   Dogecoin was created by Billy Markus from Portland, Oregon and  Jackson Palmer from Sydney, Australia. Both wanted to create a fun cryptocurrency that will appeal beyond the core Bitcoin audience. Dogecoin is primarily used as a tipping system on Reddit and Twitter where users tip each other for creating or sharing good content. The community is very active in organising fundraising activities for deserving causes.  The developers of Dogecoin haven’t made any major changes to the coin since 2015. This means that Dogecoin could get left behind and is why Shibas are leaving Dogecoin to join more advanced platforms like Ethereum. One of Dogecoin strengths is its relaxed and fun-loving community. However, this is also a weakness because other currencies are way more professional.  To purchase Dogecoin, it involves downloading a crypto wallet, setting up a crypto exchange account and then trading away for your desired crypto currency. Once we have set up an account with a DOGE currency exchange and deposited some funds, you are ready to start trading.

Dogecoin

Dogecoin is currently a focal point for year-end tax loss selling, leading to sharp price movements and a polarized community discussion. Many foresee further declines for the meme coin, while a resilient group of long-term holders views the current dip as a strategic accumulation opportunity for future crypto cycles, with eyes on a potential rally in 2026.

Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, Tradipitant, Trichostatin, and AQW051. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.

Vanda Pharmaceuticals Inc

Vanda Pharmaceuticals is trending significantly following the FDA approval of NEREUS, marking the first new pharmacologic treatment for motion-induced vomiting in over four decades. The community is actively discussing the drug's potential beyond motion sickness, particularly its vast opportunity in addressing GLP-1 induced nausea, which many see as a transformative revenue driver for the company. With analysts raising price targets and whispers of potential buyout interest, investors anticipate continued upside as the market fully prices in this key regulatory win and the company's robust pipeline.

ESH Acquisition Corp. is a blank check company. It was formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. The company was founded on November 17, 2021 and is headquartered in New York, NY.

ESH Acquisition Corp - Ordinary Shares - Class A

ESH Acquisition Corp (ESHA) is trending within a volatile low-float SPAC sector, fueled by discussions surrounding its extremely tight share float and high insider ownership. The community is actively debating its potential for rapid price movement and a short squeeze, drawing comparisons to other recently surging SPACs as new utility via a planned reward token is also highlighted.

Corcept Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the business of discovering and developing pharmaceutical products and medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders by modulating the effects of the hormone cortisol. The company was founded by David B. Singer and Joseph K. Belanoff on May 13, 1998 and is headquartered in Redwood City, CA.

Corcept Therapeutics Inc

Corcept Therapeutics (CORT) is trending with significant volatility after receiving an FDA Complete Response Letter for its relacorilant drug, triggering a sharp decline in shares. The community is fiercely divided, with many calling the sell-off an overreaction given the company's existing profitable drug and deep pipeline, while others foresee further downside following analyst downgrades and a need for more clinical evidence. This binary regulatory event has intensified speculation, as investors weigh potential recovery against lingering uncertainty.

Xeris Biopharma Holdings, Inc. is a biopharmaceutical company, which engages in developing and commercializing products across a range of therapies. The company has three commercial products: Gvoke, Keveyis, and Recorlev. Gvoke is ready-to-use liquid glucagon for the treatment of severe hypoglycemia. Keveyis is the therapy approved in the United States to treat hyperkalemic, hypokalemic, and related variants of primary periodic paralysis (PPP). Recorlev is a cortisol synthesis inhibitor approved for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome. Its product also includes Ogluo which is used for the treatment of severe hypoglycemia in adults, adolescents, and children aged 2 years and over with diabetes mellitus. The company was founded by Steven Prestrelski in 2005 and is headquartered in Chicago, IL.

Xeris Biopharma Holdings Inc

Xeris Biopharma is trending after a competitor's drug for Cushing's syndrome received a regulatory setback from the FDA, which the community views as a significant advantage for Xeris's approved treatment, Recorlev. This development is seen as clearing the path for Recorlev to gain market share, fueling discussions among investors about the company's long-term growth potential and undervaluation, supported by positive analyst outlooks.

Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which engages in the development of novel therapies for the management of central nervous system disorders. Its portfolio consists of Products Overview and Pipeline Overview. The Products Overview includes Auvelity and Sunosi. The Pipeline Overview refers to AXS-05, AXS-07, AXS-12, and AXS-14. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.

Axsome Therapeutics Inc

Axsome Therapeutics is trending following the FDA's acceptance and priority review of AXS-05 for Alzheimer's disease agitation, alongside positive feedback supporting an upcoming NDA for AXS-12 in narcolepsy. The market is reacting strongly to this dual pipeline advancement, with community members expressing high optimism and noting significant short-covering as a key driver of the momentum.

What is Amp?  Amp is described as the new digital collateral token offering instant, verifiable assurances for any kind of value transfer. Using Amp, networks like Flexa can quickly and irreversibly secure transactions for a wide variety of asset-related use cases.  How does Amp work?  Amp claims to offer a straightforward but versatile interface for verifiable collateralization through a system of collateral partitions and collateral managers. Where collateral partitions can be designated to collateralize any account, application, or even transaction, and carry balances which are directly verifiable on the Ethereum blockchain, collateral managers are smart contracts that can lock, release, and redirect collateral in these partitions as needed in order to support value transfer activities. Amp supports a wide variety of use cases for collateralization, and also introduces the concept of predefined partition strategies, which can enable special capabilities such as collateral models through which tokens can be staked without ever leaving their original address.

AMP Token

AMP is trending as its community intensely debates future prospects amid persistent price challenges. Significant anticipation surrounds potential regulatory clarity from the "Clarity Act" and major developments like integrations with large retailers and payment networks. Despite widespread frustration over price action, many remain bullish, highlighting AMP's core utility in secure digital payments and its existing merchant adoption as crucial for eventual upside.

NIKE, Inc. engages in the design, development, marketing, and sale of athletic footwear, apparel, accessories, equipment, and services. It operates through the following segments: North America, Europe, Middle East, and Africa (EMEA), Greater China, Asia Pacific and Latin America (APLA), Global Brand Divisions, Converse, and Corporate. The North America, EMEA, Greater China, and APLA segments refer to the design, development, marketing, and selling of athletic footwear, apparel, and equipment. The Global Brand Divisions segment represents its NIKE Brand licensing businesses. The Converse segment designs, markets, licenses, and sells casual sneakers, apparel, and accessories. The Corporate segment is composed of unallocated general and administrative expenses. The company was founded by William Jay Bowerman and Philip Hampson Knight on January 25, 1964 and is headquartered in Beaverton, OR.

Nike, Inc. - Ordinary Shares - Class B

Nike Inc

Nike is trending as the community buzzes over significant insider purchases by its CEO and Apple's CEO, interpreting these moves as a strong vote of confidence. Many are viewing this as a signal for a potential turnaround, fueling discussions of a short squeeze and a rebound from recent lows, with some anticipating substantial upside driven by future sporting events and strategic shifts.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>According to data from the CME FedWatch tool, the probability of a 25-basis-point rate cut in January is now at 14.9%, down from 23% a month ago.&nbsp;</li><li>The probability for a 25 bps cut in March remains relatively high, at 42.5%, compared to 38.5% a month ago.</li><li>According to the Fed’s dot-plot projections, the median estimate for the federal funds rate at the end of 2026 is 3.4%, which is a quarter point lower than the current range of 3.5% and 3.75%.</li></ul>As 2025 draws to a close, investors are trying to decode where the Federal Reserve’s monetary policy is headed next.After holding rates steady for most of 2025 and resisting President Donald Trump’s calls for rate cuts, the central bank ended the year with three consecutive 25 basis point reductions in the policy rate.With the labor market cooling and inflation remaining above the Fed’s long-term target of 2%, markets are lowering their expectations of aggressive cuts in the coming year.<h2 class="st-heading-2">What Are Markets Considering?</h2>According to data from the CME FedWatch&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.cmegroup.com/markets/interest-rates/cme-fedwatch-tool.html">tool</a>, the probability of a 25-basis-point rate cut in January is now at 14.9%, down from 23% a month ago.&nbsp;The probability for a 25 bps cut in March remains relatively high, at 42.5%, compared to 38.5% a month ago.However, the odds of the federal funds rate being in the 3% to 3.25% range, which implies a cumulative reduction of 50 bps, are considerably low, at 5.9%. This is down from 8.1% a month ago.<h2 class="st-heading-2">Economist’s Take</h2>Jeremy Siegel, professor emeritus of finance at the University of Pennsylvania’s Wharton School of Business, stated last week that cooling inflation gives the Federal Reserve more room to move the policy rate down further. Eventually, he expects additional easing that will take rates closer to the low-3% range.According to the Fed’s dot-plot projections, the median estimate for the federal funds rate at the end of 2026 is 3.4%, which is a quarter point lower than the current range of 3.5% and 3.75%. This points to just one cut in 2026.<h2 class="st-heading-2">Fed’s Pivot</h2>The Federal Open Market Committee (FOMC) met eight times in 2025 and chose to keep rates unchanged in the first five meetings.The central bank noted in its first five meetings that the labor market conditions were “solid,” but changed its tone in the sixth meeting in September, with the FOMC statement stating that “job gains have slowed this year” in the last three meetings of the year. However, its tone on inflation was consistent throughout the year, with the central bank stating that it remained “somewhat elevated.”Inflation remained above the Fed’s long-term target of 2%, and the central bank expects it to stay above this level throughout 2026 as well as 2027.The Fed also ended its Quantitative Tightening (QT) program on December 1, bringing an end to a multi-year effort to reduce its balance sheet.<h2 class="st-heading-2">Growing Dissent</h2>Dissent among central bank officials has been growing. The first four FOMC meetings saw unanimous agreement among the committee's voting members on the rate policy, but since the fifth meeting, there has been dissent.Notable among the dissenters this year is Fed Governor Stephen Miran, who has voted for a 50 bps cut thrice since being sworn in to the position in September.During the December FOMC meeting, there were three dissenters against the central bank’s monetary policy action — while Miran wanted a larger 50 bps cut, Austan Goolsbee and Jeffrey Schmid wanted no cuts.According to a CNBC&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.cnbc.com/2025/12/10/the-fed-is-the-most-divided-its-been-in-more-than-a-decade.html">report</a>, this is the most divisive the Fed has been in the past six years.<h2 class="st-heading-2">Leadership Change Ahead</h2>Fed Chair Jerome Powell’s term is set to expire in May 2026. President Trump told reporters on Tuesday that he plans to announce his pick for the Fed Chair position sometime in January, after threatening to sue Powell for “gross incompetence,”&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.reuters.com/world/us/trump-threatens-sue-feds-powell-will-announce-replacement-next-month-2025-12-29/">according</a> to Reuters.There are two <a href="https://stocktwits.com/news-articles/markets/equity/kevin-warsh-fed-chair-kalshi-after-pushback-against-kevin-hassett-trump/cLeJfHqREYv">frontrunners</a> for the Fed Chair role — White House National Economic Council Director Kevin Hassett and former Fed Governor Kevin Warsh, with Christopher Waller also in the running.Meanwhile, U.S. equities declined in Wednesday morning’s trade. At the time of writing, the&nbsp;<a href="https://stocktwits.com/symbol/SPY">SPDR S&amp;P 500 ETF</a> (SPY), which tracks the S&amp;P 500 index, was down 0.35%; the Invesco QQQ Trust ETF (QQQ) fell 0.38%; and the&nbsp;<a href="https://stocktwits.com/symbol/DIA">SPDR Dow Jones Industrial Average ETF Trust</a> (DIA) declined 0.35%. Retail sentiment around the S&amp;P 500 ETF on Stocktwits was in the ‘neutral’ territory.The&nbsp;<a href="https://stocktwits.com/symbol/TLT">iShares 20+ Year Treasury Bond ETF</a> (TLT) was down 0.18% at the time of writing, while the&nbsp;<a href="https://stocktwits.com/symbol/IEF">iShares 7-10 Year Treasury Bond ETF</a> (IEF) fell 0.1%.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/why-is-inbs-stock-rising-today/cL7BB78REzv">Why Is INBS Stock Rising Today?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, The Federal Reserve System logo displayed on a smartphone. 

How Fed’s 2025 Pivot, QT Exit, And Rising Dissent Reshaped Rate Expectations This Year

After holding rates steady for most of 2025 and resisting President Donald Trump’s calls for rate cuts, the central bank ended the year with three consecutive 25 basis point reductions in the policy rate.

Equity

<ul class="summary-bullets"><li>Experts at ING Think stated in a recent note that they expect the Q4 GDP growth to be “considerably slower.”</li><li>The firm also expects a slowdown in consumer spending during the quarter.</li><li>Analysts say a mix of tepid fourth-quarter growth forecasts and deeper structural market forces is keeping long-term yields from collapsing.</li></ul>U.S. Treasury Yields were muted on Friday morning as investors returned to the markets in a holiday-shortened week, even as analysts expect muted growth in the fourth quarter.The benchmark 10-Year Treasury yield fell one basis point to 4.132%, while the 30-year yield gained one basis point to 4.801%. The 2-year Treasury yield declined two basis points to hover at 3.493% at the time of writing.Analysts say a mix of tepid fourth-quarter (Q4) growth forecasts and deeper structural market forces is keeping long-term yields from collapsing, reflecting macroeconomic caution and persistent term-premium pressures.“You can’t have inflation and growth running at this pace and expect 10-year yields to move much lower,” said Gregory Faranello, head of U.S. rates strategy at AmeriVet Securities, according to a&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.cnbc.com/2025/12/26/treasury-yields-are-little-changed-as-traders-return-from-christmas-holiday.html">report</a> by CNBC.<h2 class="st-heading-2">Growth Slowdown Likely</h2>Analysts at ING Think stated in a recent note that they expect the Q4 Gross Domestic Product (GDP) growth to be “considerably slower,” following the third-quarter (Q3)&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/us-gdp-q3-december-2025/cLep8gzREuU">GDP surprise</a>.The firm tempered its expectations for Q4 GDP due to the 43-day-long U.S. government shutdown, and expects a slowdown in consumer spending as well during the quarter.“Expectations of cooling data probably explains the relatively muted market reaction with the 10Y Treasury yield only up 3bp on the day [of GDP report release] and Fed funds rate cut expectations for 2026 still holding above 50bp,” the firm said.<h2 class="st-heading-2">Rate Cut Outlook</h2>Jeremy Siegel, professor emeritus of finance at the University of Pennsylvania’s Wharton School of Business, on Tuesday stated that he expects cooling inflation to give the Federal Reserve more room to lower the policy rate further. He expects additional easing that will take rates closer to the low-3% range.According to data from the CME FedWatch&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.cmegroup.com/markets/interest-rates/cme-fedwatch-tool.html">tool</a>, the probability of a 25-basis-point rate cut in January is now at 17.7%, down from 22.1% a week ago.However, Siegel still does not see a collapse in longer yields even if the policy rate is lowered. “I do not expect that to automatically pull the 10-year down by the same magnitude. The long end is likely to remain anchored in the low-4% area as term premium, issuance, and structural forces keep longer yields from collapsing,” he said.<h2 class="st-heading-2">Entry Points To Become Attractive</h2>Analysts at Nuveen stated in their latest note that the entry points for Treasuries will become attractive going forward.“Risk premiums may widen further, with entry points likely to become more attractive over the coming quarters. Duration is likely to reassume its role as a growth hedge,” the firm said.It added that current yields present compelling opportunities for investors, while noting material downside risks to the U.S. economy. The firm said that tariffs are likely to compress consumer spending and weigh on business fixed investment, but it still does not have a recession as its base case.<h2 class="st-heading-2">Key Data</h2>While the earnings season is drawing to a close, investors will keep an eye on the Federal Open Market Committee’s (FOMC) minutes from the December meeting, scheduled to be released on Tuesday.Home sales data on Monday, and the S&amp;P Case-Shiller home price index on Tuesday will also be on investors’ radars next week.The weekly jobless claims report from the U.S. Department of Labor will also be keenly monitored.The&nbsp;<a href="https://stocktwits.com/symbol/TLT">iShares 20+ Year Treasury Bond ETF</a> (TLT) was up 0.15% at the time of writing, while the&nbsp;<a href="https://stocktwits.com/symbol/IEF">iShares 7-10 Year Treasury Bond ETF</a> (IEF) was up 0.16%. Retail sentiment around the TLT ETF was in the ‘bullish’ territory.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/is-the-stock-market-open-today-after-christmas/cLeUEoAREw0">Is The Stock Market Open Today? NYSE, Nasdaq Trading Hours For December 26</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

US Treasury Yields | Representative image

Treasury Yields Hold Steady As Wall Street Braces For ‘Considerably Slower’ Q4 GDP

The benchmark 10-year Treasury yield fell one basis point to 4.132%, while the 30-year yield gained one basis point to hover at 4.801%.

November Inflation Cools: ETF Strategies to Play 

Cooling November inflation revives rate-cut bets. Investors eye TLT, GLD, SPYG and high-income ETFs like VYM, SDIV, KNG and DIV.

Better U.S. Treasury Bond ETF: Vanguard Long-Term Treasury Fund vs. iShares 20+ Year Treasury Bond ETF

Key PointsThe Vanguard Long-Term Treasury Fund (VGLT) and iShares 20+ Year Treasury Bond ETF (TLT) focus on slightly different U.S. Treasury bonds...

Analysts revamp forecasts as gold prices hit wall

Gold prices soared to all-time highs this year due to economic worries fueled by job losses and the tariffs-driven trade war. The precious metal has risen over 50% year-to-date, including a 20% surge...

US Government Shutdown Puts These ETFs in Focus

The U.S. government shut down on Oct. 1, 2025, as last-minute talks failed. ETFs like TLT, XLV and PSCC hog attention. 

ETF Strategies to Follow as Powell Hints at September Rate Cuts

Fed Chair Powell signaled a September rate cut, triggering rallies in stocks, bonds and cryptos. ETFs like GOVT, SDIV, SPYG, IBIT, VNQ and XLU are set to gain. 

ETF Asset Report of June 2025

QQQ, IBIT and GLD led ETF inflows in June as tech gains, crypto momentum and safe-haven demand shaped investor bets.

Gross predicts little bull market for stocks, bear for bonds

Investing.com -- Billionaire investor Bill Gross shared his market outlook on Tuesday through a post on social media platform X, offering predictions for both stock and bond markets.

Israel's Strikes on Iran Boost Safe Haven ETF Demand 

BlackRock Institutional Trust Company N.A. - iShares 20+ Year Treasury Bond ETF

Tlt etf stock price, news, financials, forum, current price, discussion, message board, community insights, and trading ideas. Join 10 million+ investors and traders tracking markets in real-time on Stocktwits.

TLT
iShares 20+ Year Treasury Bond ETF

Feed

News

Sentiment

Fundamentals

Info

Latest TLT News

TLTiShares 20+ Year Treasury Bond ETF